XSTOISOFOL
Market cap34mUSD
Dec 23, Last price
2.34SEK
1D
-2.50%
1Q
-11.03%
IPO
-91.20%
Name
Isofol Medical AB (publ)
Chart & Performance
P/E
—
P/S
524.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.44%
Rev. gr., 5y
-11.85%
Revenues
721k
-94.37%
Net income
-37m
L-76.23%
CFO
-53m
L-72.49%
Earnings
Feb 19, 2025
Profile
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 721 -94.37% | 12,797 -42.89% | 22,407 -39.63% | ||||||
Cost of revenue | 35,136 | 178,504 | 422,741 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (34,415) | (165,707) | (400,334) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (3,812) | (3,367) | |||||||
Tax Rate | |||||||||
NOPAT | (34,415) | (161,895) | (396,967) | ||||||
Net income | (37,071) -76.23% | (155,943) -20.79% | (196,884) 4.18% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 23 | 452,025 | |||||||
BB yield | -0.02% | -38.94% | |||||||
| Debt | |||||||||
Debt current | 1,543 | 1,542 | |||||||
Long-term debt | 6,353 | 1,762 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 911 | 846 | |||||||
Net debt | (138,148) | (182,737) | (381,153) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (52,536) | (190,975) | (188,429) | ||||||
CAPEX | |||||||||
Cash from investing activities | 101 | ||||||||
Cash from financing activities | (1,681) | 450,477 | |||||||
FCF | (30,404) | (164,163) | (395,455) | ||||||
| Balance | |||||||||
Cash | 138,148 | 190,583 | 379,448 | ||||||
Long term investments | 50 | 5,009 | |||||||
Excess cash | 138,112 | 189,993 | 383,337 | ||||||
Stockholders' equity | (1,096,844) | (1,059,129) | (899,375) | ||||||
Invested Capital | 1,219,188 | 1,222,401 | 1,219,260 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 161,515 | 161,515 | 125,645 | ||||||
Price | 0.73 -1.35% | 0.74 -91.99% | 9.24 -58.25% | ||||||
Market cap | 117,906 -1.35% | 119,521 -89.70% | 1,160,961 -32.55% | ||||||
EV | (20,242) | (63,216) | 779,808 | ||||||
EBITDA | (34,378) | (164,065) | (398,738) | ||||||
EV/EBITDA | 0.59 | 0.39 | |||||||
Interest | 44 | 168 | |||||||
Interest/NOPBT | |||||||||